

Innovation at Work California



Research in the Golden State

The Salk Institute of Biological Sciences, University of California, San Diego (UCSD), and Nimbus Therapeutics, La Jolla, CA

In a National Institutes of Health (NIH) and Department of Defense (DoD)-funded collaboration between the Salk Institute, UCSD and Nimbus Therapeutics, researchers are working to develop a new treatment to inhibit cancer growth by interrupting an enzyme vital to lipid synthesis.

University of California, Davis, Davis, CA

The National Institutes of Health (NIH) is supporting neuroscientists at UC Davis working to discover microstructures related to attention in the brain. Better understanding of these brain systems could lead to improved treatments for attention disorders associated with psychiatric and neurological diseases, including attention deficit disorder, Parkinson's and Alzheimer's disease.

Genentech, Carlsbad, Carmichael, Fullerton, La Jolla, and Torrance, CA

Genentech is conducting phase III clinical trials to test the safety and efficacy of a new drug for multiple sclerosis (MS). The treatment is specifically intended for patients who have not experienced success with currently available therapies.

SOURCES: NATIONAL INSTITUTES OF HEALTH (NIH), PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA), CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), A RESEARCHIAMERICA SURVEY OF U.S. ADULTS CONDUCTED IN PARTNERSHIP WITH ZOGBY ANALYTICS IN JANUARY 2017, CLINICALTRIALS.GOV, THE SALK INSTITUTE, NATIONAL SCIENCE FOUNDATION (NSF), UC DAVIS.